Aytu BioPharma (AYTU) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $57M

Market Cap: $26.7MFounded: 2015HQ: Greenwood Village, United States

Sector Ranking#78 in Neuroscience & CNS #129 in Diagnostics & Precision Medicine

Overview

Aytu BioPharma is a publicly traded, commercial-stage company with a mission to become a leading CNS-focused specialty pharma by commercializing novel therapeutics and ensuring broad patient access. Its core strategy leverages a dual-portfolio approach: a high-growth CNS franchise anchored by the recently launched EXXUA™ for MDD and an ADHD portfolio, alongside a legacy non-CNS business that provides stable cash flow. The company differentiates itself through its integrated commercial engine, particularly the Aytu RxConnect patient support program, aiming to overcome market access barriers in complex CNS markets.

PsychiatryCentral Nervous System

Technology Platform

Aytu's core platform is commercial: the Aytu RxConnect patient support program, a comprehensive hub service designed to optimize patient access, reimbursement, and adherence for its CNS therapies.

Funding History

3

Total raised:$57M

IPO$12MUndisclosedFeb 15, 2018

Series B$30MUndisclosedSep 15, 2017

Series A$15MUndisclosedApr 15, 2015

Opportunities

The launch of EXXUA™, a first-in-class treatment for MDD, addresses a massive market with high unmet need for novel, non-SSRI mechanisms.

The scalable Aytu RxConnect platform provides a competitive service advantage in ensuring patient access and can be leveraged for future CNS product launches.

Risk Factors

Commercial success is heavily concentrated on the uptake of EXXUA™, facing intense competition and reimbursement challenges in the crowded MDD market.

The company's limited financial resources as a micro-cap stock create execution risk and potential for dilution if the launch does not generate sufficient cash flow rapidly.

Competitive Landscape

Aytu competes in highly saturated markets: EXXUA™ faces off against generic SSRIs/SNRIs and newer branded MDD therapies, while its ADHD portfolio battles a deep field of stimulants and non-stimulants. Its primary differentiation is its service-oriented commercial model via the Aytu RxConnect access platform.